Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To examine clinicopathologic correlations in early vs late age at onset frontotemporal dementia (FTD) and frontotemporal lobar degeneration (FTLD).
Methods All patients were clinically evaluated and prospectively diagnosed at the UCSF Memory and Aging Center. Two consecutive series were included: (1) patients with a clinically diagnosed FTD syndrome who underwent autopsy (cohort 1) and (2) patients with a primary pathologic diagnosis of FTLD, regardless of the clinical syndrome (cohort 2). These series were divided by age at symptom onset (cutoff 65 years).
Results In cohort 1, 48 (25.3%) were 65 years or older at symptom onset. Pathologic causes of behavioral variant FTD (bvFTD) were similar in the early age at onset (EO) and late age at onset (LO) bvFTD groups. In corticobasal syndrome (CBS), however, the most common pathologic substrate differed according to age at onset: progressive supranuclear palsy (42.9%) in LO-CBS and Alzheimer disease (AD; 40.7%) in EO-CBS. In cohort 2, 57 (28.4%) were classified as LO-FTLD. Regarding FTLD major molecular classes, FTLD with transactive response DNA-binding protein of 43 kDa was most common in EO-FTLD (44.4%), whereas FTLD-tau (58.3%) was most common in LO-FTLD. Antemortem diagnosis of a non-FTD syndrome, usually AD-type dementia, was more frequent in LO-FTLD than EO-FTLD (19.3% vs 7.7%, p = 0.017). LO-FTLD was also associated with more prevalent comorbid pathologic changes. Of these, moderate to severe AD neuropathologic change and argyrophilic grain disease were overrepresented among patients who received an antemortem diagnosis of AD-type dementia.
Conclusion Patients with FTD and FTLD often develop symptoms after age 65, and age at onset represents an important consideration when making antemortem neuropathologic predictions.
Glossary
- Aβ=
- β-amyloid;
- AD=
- Alzheimer disease;
- ADNC=
- Alzheimer disease neuropathologic change;
- AGD=
- argyrophilic grain disease;
- bvFTD=
- behavioral variant frontotemporal dementia;
- CAA=
- cerebral amyloid angiopathy;
- CBD=
- corticobasal degeneration;
- CBS=
- corticobasal syndrome;
- EO=
- early age at onset;
- FTD=
- frontotemporal dementia;
- FTLD=
- frontotemporal lobar degeneration;
- FUS=
- fused in sarcoma;
- HS=
- hippocampal sclerosis;
- LO=
- late age at onset;
- MND=
- motor neuron disease;
- NIA=
- National Institute on Aging;
- PSP=
- progressive supranuclear palsy;
- PSPS=
- progressive supranuclear palsy syndrome;
- svPPA=
- semantic variant primary progressive aphasia;
- TDP-43=
- TAR DNA-binding protein of 43 kDa;
- UCSF MAC=
- University of California San Francisco Memory and Aging Center;
- VBI=
- vascular brain injury
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
CME Course: NPub.org/cmelist
- Received June 2, 2017.
- Accepted in final form January 2, 2018.
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in agingAlifiya Kapasi, Lei Yu, Patricia A. Boyle et al.Neurology, August 04, 2020 -
Article
Coexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degenerationShelley L. Forrest, Daniel R. Crockford, Anastasia Sizemova et al.Neurology, April 24, 2019 -
Article
Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrumLieke H.H. Meeter, Everard G. Vijverberg, Marta Del Campo et al.Neurology, March 07, 2018 -
Articles
The heritability and genetics of frontotemporal lobar degenerationJ. D. Rohrer, R. Guerreiro, J. Vandrovcova et al.Neurology, November 02, 2009